

### Randomized Trial to Prevent Vascular Events in HIV

#### **September 2023 Table of Contents**

- Trial Status: We Achieved 100% of Participants Off Study!
- REPRIEVE Community Forums in September
- Study Closure Reminders and FAQ
- REPRIEVE Feature in The New York Times
- NEJM Podcast: Preventing HIV's Collateral Cardiovascular Damage
- August 2023 MOB Newsletter
- Join Us for the Next Team/Site Call Tuesday September 19th
- Are You Up to Date?



# Trial Status: We Achieved 100% of Participants Off Study!

We are happy to share that thanks to an incredible effort by each and every site team, 100% of participants are now offstudy!!!

REPRIEVE Leadership recognizes this incredible accomplishment, and is incredibly appreciative of the hard work put in by EVERYONE to achieve this milestone!!!

Please Promote REPRIEVE Community Forums



Please share information about these important events with REPRIEVE participants, and anyone else you think would be interested in joining!

For more information, visit the REPRIEVE

website: https://www.reprievetrial.org/for-participants/community-forum/.

### Study Closure Reminders and FAQ




**Shipping Deadline:** All specimens from site labs are to be sent to BRI by September 18th, 2023.

If you are at a non-ACTG site in the US or Canada and need a shipping label, please email <a href="mailto:mghreprieveshipping@partners.org">mghreprieveshipping@partners.org</a>

**Query Response Deadline:** The deadline for site responses and corrections is October 16th 2023.

Click here to download slides the REPRIEVE Data Managers developed on this topic.



Or go to the FSTRF YouTube channel to access an instructional video <a href="https://example.com/here">here</a>



- **Q.** When can I deregister the REPRIEVE (A5332) protocol with DAIDS protocol registration?
- **A.** The REPRIEVE study closure SOP indicates that deregistration of the protocol with DAIDS protocol registration is to occur *after* confirmation of study closure with the site's IRB/EC (January 1, 2024). Study closure with the site's IRB/EC is to be completed after unblinding (November 20th, 2023).



# We are so excited to share two recent media showcasing REPRIEVE!

### The New York Times


## For 'Silver Tsunami' With H.I.V., New Hope for Healthy Aging

A recent study showed that a statin drug significantly lowered the risk of heart attacks and strokes among middle-aged and older people with the virus.

"This is really an important study," said Dr. Anthony S. Fauci, who as the former director of the National Institute of Allergy and Infectious Diseases — he retired in December — was among the N.I.H.'s leaders who approved Reprieve's mammoth budget. "The results, in some respects — they're even better than I would have expected."

On September 10th, The New York Times featured REPRIEVE as part of the new hope for people aging with HIV. The article includes quotes from Dr. Anthony Fauci and REPRIEVE Co-PI Dr. Steven Grinspoon! Click here to access the article.





## NEJM Podcast: Preventing HIV's Collateral Cardiovascular Damage

The New England Journal of Medicine's Intention to Treat series recently reviewed the results of REPRIEVE!

Click here to listen to interviews with REPRIEVE Co-PI Dr. Steven Grinspoon and two individuals with HIV as they discuss the meaning of REPRIEVE's results for PWH.

Please share these links with REPRIEVE participants, clinicians, and the HIV community in your area.

For more news updates, please refer to the REPRIEVE website: <a href="https://www.reprievetrial.org/learnmore/news/">https://www.reprievetrial.org/learnmore/news/</a>.



### **August 2023 MOB Newsletter**

The Office of Clinical Site Oversight has asked us to share the August 2023 20th edition of the OCSO MOB Newsletter! You can read the newsletter by clicking the link <a href="here">here</a>.



### Join Us for the Next Team/Site Call Tuesday September 19th

If you have any questions in advance of the site call we'd love to hear from you!

Please email them to Katie Fitch at the REPRIEVE CCC.

Note that REPRIEVE will continue to hold monthly site calls during study closure to share important updates and answer any questions sites may have.

12:00 PM PERU (PET) 1:00 PM US (EDT) 1:00 PM HAITI (EDT) 1:00 PM PUERTO RICO (AST) 2:00 PM BRAZIL (BRT)
7:00 PM BOTSWANA (CAT)\*\*\*
7:00 PM SOUTH AFRICA (SAST)\*\*\*
7:00 PM ZIMBABWE (CAT)\*\*\*
8:00 PM UGANDA (EAT)\*\*\*
10:30 PM INDIA (IST)\*\*\*

12:00 AM (May 17th 2023) THAILAND (ICT)\*\*\*

\*\*\*We do not expect site staff to join these calls during their off-work hours. Instead, we will post slides from this call on the A5332 PSWP.

Remember that questions are always welcome at <a href="actg.corea5332@fstrf.org">actg.corea5332@fstrf.org</a>

## REPRIEVE (A5332): Are You Up to Date? For A5332 please use:

Protocol Version 6.0 dated 05/16/2022
MOPS Version 6.0 dated 12/14/2022
LPC for ACTG Sites Version 6.0 dated 06/03/2022
LPC for Non-ACTG Sites Version 6.0 dated 09/08/2022
FAQs dated 09/02/2022
Coenrollment Guidelines dated 02/06/2023
These documents are on the A5332 PSWP

### For future reference, all newsletters are available on the REPRIEVE Website

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at <a href="mailto:reprieve.news@fstrf.org">reprieve.news@fstrf.org</a>







Like, comment, share, and retweet!

#### REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital 55 Fruit Street, 5LON 207 Boston, MA USA 02114

Want to change how you receive these emails? You can update your preferences or unsubscribe from this list.

#### This email was sent to <a href="mailto:mdiggs@mgh.harvard.edu">mdiggs@mgh.harvard.edu</a>

 $\frac{\textit{why did I get this?}}{\textit{Massachusetts General Hospital}} \quad \frac{\textit{update subscription preferences}}{\textit{Value of the preferences}} \quad \frac{\textit{update subscription preferences}}{\textit{Value of$ 

